Compare LCTX & FSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | FSP |
|---|---|---|
| Founded | 1990 | 1981 |
| Country | United States | United States |
| Employees | 77 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.4M | 48.2M |
| IPO Year | 1996 | 2001 |
| Metric | LCTX | FSP |
|---|---|---|
| Price | $1.01 | $0.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.25 | N/A |
| AVG Volume (30 Days) | ★ 846.4K | 506.0K |
| Earning Date | 05-14-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 6.34% |
| EPS Growth | N/A | ★ 15.69 |
| EPS | ★ N/A | N/A |
| Revenue | $14,556,000.00 | ★ $107,162,000.00 |
| Revenue This Year | $109.40 | $17.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 53.24 | N/A |
| 52 Week Low | $1.00 | $0.37 |
| 52 Week High | $2.09 | $1.73 |
| Indicator | LCTX | FSP |
|---|---|---|
| Relative Strength Index (RSI) | 37.52 | 28.19 |
| Support Level | N/A | N/A |
| Resistance Level | $1.18 | $0.51 |
| Average True Range (ATR) | 0.05 | 0.02 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 10.81 | 1.20 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.